488 related articles for article (PubMed ID: 3489425)
1. Surfactant phospholipids and lavage phospholipase A2 in experimental Pneumocystis carinii pneumonia.
Sheehan PM; Stokes DC; Yeh YY; Hughes WT
Am Rev Respir Dis; 1986 Sep; 134(3):526-31. PubMed ID: 3489425
[TBL] [Abstract][Full Text] [Related]
2. Regulation of surfactant phosphatidylcholine secretion from alveolar type II cells during Pneumocystis carinii pneumonia in the rat.
Rice WR; Singleton FM; Linke MJ; Walzer PD
J Clin Invest; 1993 Dec; 92(6):2778-82. PubMed ID: 8254031
[TBL] [Abstract][Full Text] [Related]
3. Comparison of dosages, intervals, and drugs in the prevention of Pneumocystis carinii pneumonia.
Hughes WT
Antimicrob Agents Chemother; 1988 May; 32(5):623-5. PubMed ID: 3260765
[TBL] [Abstract][Full Text] [Related]
4. Phospholipase activities of bronchoalveolar lavage fluid in rat Pneumocystis carinii pneumonia.
Kernbaum S; Masliah J; Alcindor LG; Bouton C; Christol D
Br J Exp Pathol; 1983 Feb; 64(1):75-80. PubMed ID: 6601489
[TBL] [Abstract][Full Text] [Related]
5. Effects of smoke inhalation on surfactant phospholipids and phospholipase A2 activity in the mouse lung.
Oulton M; Moores HK; Scott JE; Janigan DT; Hajela R
Am J Pathol; 1991 Jan; 138(1):195-202. PubMed ID: 1987765
[TBL] [Abstract][Full Text] [Related]
6. Effect of folinic acid on the capacity of trimethoprim-sulfamethoxazole to prevent and treat Pneumocystis carinii pneumonia in rats.
D'Antonio RG; Johnson DB; Winn RE; van Dellen AF; Evans ME
Antimicrob Agents Chemother; 1986 Feb; 29(2):327-9. PubMed ID: 3487285
[TBL] [Abstract][Full Text] [Related]
7. Alteration of surfactant proteins A and D in bronchoalveolar lavage fluid of Pneumocystis carinii pneumonia.
Qu J; He L; Rong Z; Pan J; Chen X; Morrison DC; Li X
Chin Med J (Engl); 2001 Nov; 114(11):1143-6. PubMed ID: 11729507
[TBL] [Abstract][Full Text] [Related]
8. Effects of sulfonylurea compounds on Pneumocystis carinii.
Hughes WT; Smith-McCain BL
J Infect Dis; 1986 May; 153(5):944-7. PubMed ID: 3486236
[TBL] [Abstract][Full Text] [Related]
9. Reduction of pulmonary surfactant in patients with human immunodeficiency virus infection and Pneumocystis carinii pneumonia.
Hoffman AG; Lawrence MG; Ognibene FP; Suffredini AF; Lipschik GY; Kovacs JA; Masur H; Shelhamer JH
Chest; 1992 Dec; 102(6):1730-6. PubMed ID: 1446480
[TBL] [Abstract][Full Text] [Related]
10. Resistance to trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia. Implication of folinic acid.
Nunn PP; Allistone JC
Chest; 1984 Jul; 86(1):149-50. PubMed ID: 6610537
[TBL] [Abstract][Full Text] [Related]
11. Pentamidine aerosol in prophylaxis and treatment of murine Pneumocystis carinii pneumonia.
Girard PM; Brun-Pascaud M; Farinotti R; Tamisier L; Kernbaum S
Antimicrob Agents Chemother; 1987 Jul; 31(7):978-81. PubMed ID: 3499116
[TBL] [Abstract][Full Text] [Related]
12. Generation of lyso-phospholipids from surfactant in acute lung injury is mediated by type-II phospholipase A2 and inhibited by a direct surfactant protein A-phospholipase A2 protein interaction.
Arbibe L; Koumanov K; Vial D; Rougeot C; Faure G; Havet N; Longacre S; Vargaftig BB; Béréziat G; Voelker DR; Wolf C; Touqui L
J Clin Invest; 1998 Sep; 102(6):1152-60. PubMed ID: 9739049
[TBL] [Abstract][Full Text] [Related]
13. Pneumocystis carinii pneumonia alters expression and distribution of lung collectins SP-A and SP-D.
Atochina EN; Beck JM; Scanlon ST; Preston AM; Beers MF
J Lab Clin Med; 2001 Jun; 137(6):429-39. PubMed ID: 11385364
[TBL] [Abstract][Full Text] [Related]
14. Limited effect of trimethoprim-sulfamethoxazole prophylaxis on Pneumocystis carinii.
Hughes WT
Antimicrob Agents Chemother; 1979 Sep; 16(3):333-5. PubMed ID: 315754
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of caspofungin, a 1,3-β-D-glucan synthase inhibitor, on Pneumocystis carinii pneumonia in rats.
Sun P; Tong Z
Med Mycol; 2014 Nov; 52(8):798-803. PubMed ID: 25288652
[TBL] [Abstract][Full Text] [Related]
16. Correlation of organism burden and alveolar macrophage counts during infection with Pneumocystis carinii and recovery.
Lasbury ME; Durant PJ; Bartlett MS; Smith JW; Lee CH
Clin Diagn Lab Immunol; 2003 Mar; 10(2):293-302. PubMed ID: 12626457
[TBL] [Abstract][Full Text] [Related]
17. Functional impairment of bronchoalveolar lavage phospholipids in early Pneumocystis carinii pneumonia in rats.
Su TH; Natarajan V; Kachel DL; Moxley MA; Longmore WJ; Martin WJ
J Lab Clin Med; 1996 Mar; 127(3):263-71. PubMed ID: 9273359
[TBL] [Abstract][Full Text] [Related]
18. Surfactant analysis during Pneumocystis carinii pneumonia in HIV-infected patients.
Escamilla R; Prevost MC; Hermant C; Caratero A; Cariven C; Krempf M
Chest; 1992 Jun; 101(6):1558-62. PubMed ID: 1600773
[TBL] [Abstract][Full Text] [Related]
19. Lung mechanics, radiography and 67Ga scintigraphy in experimental Pneumocystis carinii pneumonia.
Stokes DC; Hughes WT; Alderson PO; King RE; Garfinkel DJ
Br J Exp Pathol; 1986 Jun; 67(3):383-93. PubMed ID: 3487339
[TBL] [Abstract][Full Text] [Related]
20. Influence of immobilization stress on the phospholipid composition of alveolar surfactant and lungs in rats.
Yanev E; Momchilova-Pankova A; Markovska T; Koumanov K; Kenarov P; McGuigan FJ; Nicolov N
Pavlov J Biol Sci; 1990; 25(1):25-8. PubMed ID: 2314936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
